NEW YORK (Reuters Health) – Use of valproate during pregnancy compared with other antiepileptic drugs is associated with reduced cognitive function in offspring at 3 years of age,…
NEW YORK (Reuters Health) – In a study of nearly 7000 men, large body size at age 20 years and subsequent weight gain were both identified as independent…
NEW YORK (Reuters Health) – From 1985 to 2007, the initial CD4+ cell counts seen at diagnosis in HIV-infected patients in the US have fallen, suggesting that the…
NEW YORK (Reuters Health) – In patients with newly diagnosed type 1 diabetes, high-dose immune ablation followed by autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT) induces significant and…
NEW YORK (Reuters Health) – In children exposed in utero to methamphetamine, MRI findings suggest alterations in white matter maturation, according to a report in the April 15th…
NEW YORK (Reuters Health) – New research suggests that marijuana use may increase the risk of testicular germ cell tumors (TGCTs), primarily nonseminoma types. According to the report…
NEW YORK (Reuters Health) – After the development of coronary artery disease (CAD), a subsequent diagnosis of depression is associated with an increased incidence of heart failure, even…
NEW YORK (Reuters Health) – Despite the fact that up to one third of patients with severe dementia receive enteral tube feeding, evidence is lacking that this practice…
Reuters Health and The Doctor’s Channel, a medical video website, today announced a joint initiative to deliver daily health news to healthcare professionals via online video newscasts. The…
NEW YORK (Reuters Health) – Assessing kidney function with both the estimated glomerular filtration rate (eGFR) and with urinary albumin levels can help predict whether chronic kidney disease…
NEW YORK (Reuters Health) – Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor, is a safe and effective treatment for hot flushes in postmenopausal women, according to a report in the…
NEW YORK (Reuters Health) – Bezafibrate, a pan-PPAR agonist used widely for treating dyslipidemia in the UK, appears to prevent or delay the development of type 2 diabetes,…
